Table 2

HRs of CHD according to different levels of BMI at baseline, during follow-up, and at last visit among patients with type 2 diabetes

BMI (kg/m2)P for trendEach 1-kg/m2 increase
<25.025.0–29.930–34.935–39.9≥40
Baseline
 Men1,5613,0082,9481,7891,649
  Number of cases350774811540451
  Person-years11,08521,19219,99011,38210,889
  Adjustment    HR (95% CI)
   Model 1a1.001.12 (0.98–1.27)1.24 (1.09–1.41)1.50 (1.31–1.72)1.39 (1.20–1.61)<0.0011.015 (1.010–1.020)
   Model 2b1.001.14 (1.00–1.29)1.27 (1.12–1.45)1.54 (1.34–1.78)1.42 (1.23–1.64)<0.0011.015 (1.011–1.020)
   Model 3c1.001.16 (1.00–1.33)1.24 (1.07–1.43)1.47 (1.26–1.72)1.45 (1.24–1.70)<0.0011.015 (1.009–1.020)
 Women1,6813,8734,7193,9685,238
  Number of cases4209041,0549381,172
  Person-years12,66430,03236,54830,10239,538
  Adjustment  HR (95% CI)
   Model 1a1.000.93 (0.83–1.05)0.92 (0.82–1.03)1.03 (0.91–1.16)1.05 (0.94–1.18)0.0101.004 (1.000–1.007)
   Model 2b1.000.95 (0.85–1.07)0.95 (0.84–1.06)1.06 (0.94–1.20)1.09 (1.00–1.22)<0.0011.004 (1.001–1.008)
   Model 3c1.000.93 (0.82–1.06)0.92 (0.82–1.05)1.02 (0.90–1.16)1.07 (0.95–1.22)0.0061.005 (1.001–1.009)
Follow-up
 Men1,4943,1083,0281,7971,528
  Number of cases335814813529435
  Person-years10,69121,87620,54211,6299,806
  Adjustment HR (95% CI)
   Model 1a1.001.14 (1.00–1.30)1.22 (1.07–1.39)1.49 (1.30–1.72)1.50 (1.29–1.74)<0.0011.017 (1.012–1.023)
   Model 2b1.001.16 (1.02–1.32)1.26 (1.11–1.44)1.53 (1.33–1.77)1.55 (1.33–1.80)<0.0011.018 (1.013–1.023)
   Model 3c1.001.18 (1.02–1.36)1.24 (1.07–1.44)1.45 (1.24–1.69)1.55 (1.31–1.82)<0.0011.017 (1.011–1.023)
 Women1,5793,8974,8743,9655,164
  Number of cases3889051,0869481,161
  Person-years12,09830,03437,74929,86239,139
  Adjustment HR (95% CI)
   Model 1a1.000.97 (0.86–1.10)0.95 (0.84–1.07)1.10 (0.98–1.25)1.10 (0.98–1.24)<0.0011.004 (1.001–1.008)
   Model 2b1.000.99 (0.88–1.12)0.98 (0.87–1.11)1.14 (1.01–1.29)1.14 (1.01–1.29)<0.0011.006 (1.002–1.009)
   Model 3c1.001.00 (0.88–1.15)1.00 (0.88–1.14)1.12 (0.98–1.28)1.12 (0.99–1.28)0.0031.005 (1.000–1.009)
Last visit
 Men1,7153,0642,8921,7131,571
  Number of cases406794782494450
  Person-years12,24121,43119,68211,10810,076
  Adjustment HR (95% CI)
   Model 1a1.001.12 (0.99–1.27)1.20 (1.06–1.36)1.44 (1.25–1.64)1.48 (1.28–1.70)<0.0011.016 (1.011–1.020)
   Model 2b1.001.15 (1.01–1.30)1.25 (1.10–1.41)1.49 (1.30–1.70)1.53 (1.32–1.76)<0.0011.016 (1.011–1.021)
   Model 3c1.001.11 (0.97–1.26)1.19 (1.04–1.37)1.33 (1.15–1.54)1.46 (1.25–1.70)<0.0011.015 (1.009–1.020)
 Women1,8913,9894,7083,8375,054
  Number of cases5029071,0399131,127
  Person-years14,25930,87436,34628,96238,442
  Adjustment HR (95% CI)
   Model 1a1.000.87 (0.78–0.97)0.87 (0.78–0.97)1.01 (0.90–1.13)1.00 (0.90–1.12)0.0221.004 (1.000–1.007)
   Model 2b1.000.89 (0.80–1.00)0.90 (0.81–1.00)1.05 (0.93–1.17)1.04 (0.93–1.17)0.0031.004 (1.001–1.008)
   Model 3c1.000.90 (0.80–1.02)0.91 (0.81–1.03)1.03 (0.92–1.17)1.00 (0.89–1.13)0.0851.003 (0.999–1.006)
  • aAdjusted for age and race.

  • bAdjusted for age, race, types of insurance, income, and smoking.

  • cAdjusted for age, race, types of insurance, income, smoking, systolic blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, HbA1c, eGFR, use of antihypertensive drugs (none, ACE inhibitor, angiotensin II receptor blockers, β-blockers, calcium channel blocker, diuretics, other antihypertensive drugs, and any two or more of above treatments), glucose-lowering agents (none, oral hypoglycemic agents, and insulin), and cholesterol-lowering agents (none, statins, and other cholesterol-lowering agents).